Skip to main content

Dose–response analysis of effects of tibolone on climacteric symptoms

Buy Article:

$43.00 plus tax (Refund Policy)


To assess the clinically optimal tibolone dose for the relief of climacteric complaints. Design

A randomised, double blind, placebo-controlled trial. Setting

Twenty-eight centres in Norway, The Netherlands, Sweden and Finland. Population

Seven hundred and seventy-five healthy postmenopausal women were randomised to tibolone in a daily dose of 0.625, 1.25, 2.5 or 5.0 mg or placebo for 12 weeks. Methods

At baseline, and after 4, 8 and 12 weeks, hot flushes, sweating, vaginal bleeding and adverse experiences were recorded. Main outcome measures

Change in frequency and intensity of hot flushes and sweating over 12 weeks. Results

From week four onwards, 2.5 and 5.0 mg tibolone were significantly more effective than placebo, regarding the frequency of hot flushes and sweating ( P < 0.001 ), whereas the 0.625 mg dose was not significantly different from placebo during the study. The frequency of hot flushes with the 1.25 mg dose was statistically significantly different from placebo, only from week eight onwards. The incidence of dropouts due to insufficient therapeutic effect was much higher in the tibolone 1.25 mg group (9.5%) than in the 2.5 (1.9%) and 5.0 mg (1.3%) groups. A dose-related increase in incidence of vaginal bleeding or spotting was observed ( P < 0.0001 ). Bleeding incidence in the 5.0 mg dose group was about twice as high as in the 2.5 mg dose group. There was no difference in incidence of adverse experiences between the 2.5- and the 1.25 mg dose group. Conclusion

A daily dose of 2.5 mg tibolone is the clinically optimal dose for the treatment of climacteric complaints in postmenopausal women.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Karolinska Hospital, Stockholm, Sweden 2: Program Management Section, NV Organon, Oss, The Netherlands 3: Clinical Development Department, NV Organon, Oss, The Netherlands 4: Clinical Trials Operations Biometrics, NV Organon, Oss, The Netherlands

Publication date: 2002-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more